Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm nivolumab in metastatic or unresectable urothelial cancer after platinum
jRCT2080222897Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in transitional cell carcinoma (TCC), sponsored by Ono Pharmaceutical. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080222897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222897.